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Abstract
Background: Reduction of gross diarrhea rate in excess of that seen over time with intravenous therapy and appropriate
antibiotics is not usually achieved by oral glucose-electrolyte rehydration therapy for cholera and cholera-like diarrheas.
Methodology and Principal Findings: This prospective randomized clinical trial at a tertiary referral hospital in southern
India was undertaken to determine whether amylase resistant starch, substituting for glucose in hypo-osmolar oral
rehydration solution, would reduce diarrhea duration and weight in adults with acute severe dehydrating diarrhea. 50 adult
males with severe watery diarrhea of less than three days’ duration and moderate to severe dehydration were randomized
to receive hypo-osmolar ORS (HO-ORS) or HO-ORS in which amylase resistant high amylose maize starch 50g/L substituted
for glucose (HAMS-ORS). All remaining therapy followed standard protocol. Duration of diarrhea (ORS commencement to
first formed stool) in hours was significantly shorter with HAMS-ORS (median 19, IQR 10-28) compared to HO-ORS (median
42, IQR 24-50) (Bonferroni adjusted P, Padj,0.001). Survival analysis (Kaplan-Meier) showed faster recovery from diarrhea in
the HAMS-ORS group (P,0.001, log rank test). Total diarrhea fecal weight in grams (median, IQR) was not significantly lower
in the HAMS-ORS group (2190, 1160-5635) compared to HO-ORS (5210, 2095-12190) (Padj=0.08). However, stool weight at
13-24 hours (280, 0-965 vs. 1360, 405-2985) and 25–48 hours (0, 0-360 vs. 1080, 55-3485) were significantly lower in HAMS-
ORS compared to HO-ORS group (Padj=0.048 and P=0.012, respectively). ORS intake after first 24 hours was lower in the
HAMS-ORS group. Subgroup analysis of patients with culture isolates of Vibrio cholerae indicated similar significant
differences between the treatment groups.
Conclusions: Compared to HO-ORS, HAMS-ORS reduced diarrhea duration by 55% and significantly reduced fecal weight
after the first 12 hours of ORS therapy in adults with cholera-like diarrhea.
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Introduction
Cholera and acute dehydrating diarrhea continue to be a major
cause of morbidity and mortality in resource poor settings. Oral
rehydration therapy using glucose salt oral rehydration solution
(ORS) is the cornerstone of treatment [1], and exploits the fact that
glucose-dependent sodium absorption in the small intestine remains
intact even as intestinal secretion continues [2]. The iso-osmolar
(compared to plasma) glucose-based oral rehydration solution
originally recommended by the World Health Organization did
not shorten the duration or severity of diarrhea and sometimes
paradoxicallyincreased diarrheavolume,leadingtopooracceptance
of ORS in many communities [3]. Studies in experimental diarrhea
indicated that reducing the glucose and sodium concentration of
ORS, resulting in osmolarity below that of plasma (hypo-osmolar
ORS), increased small intestinal water absorption compared to the
iso-osmolar ORS [4]. A meta-analysis of the resulting clinical trials
concluded that hypo-osmolar ORS reduced diarrhea in non-cholera
illness by 20% compared to conventional ORS [5]. In 2003, the
World Health Organization recommended that ORS osmolarity
and sodium content be reduced [6,7].
The colon is capable of absorbing a considerable amount of salt
and water under conditions of stress as occurs in secretory diarrhea
[8]. Complex carbohydrates such as rice powder have been used
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1587in place of glucose in ORS and have been widely accepted [9]. It
has been hypothesized that complex carbohydrate provides
glucose at the mucosal interface without introducing an osmotic
penalty [10]. However, an alternative explanation is that a
proportion of complex carbohydrate passes into the colon to be
fermented to short chain fatty acids (SCFA), which are known to
stimulate sodium and water absorption from the secreting colon
[11]. High amylose maize starch (HAMS), obtained from a
particular variety of corn, contains both an amylase-digestible
component that provides glucose by enzymatic digestion in the
small intestine (without osmotic penalty) and a high proportion of
amylase-resistant starch that is not absorbed in the small intestine
and therefore reaches the colon [12]. HAMS, given orally,
increased fecal SCFA concentrations in healthy volunteers [13]. In
adults with cholera, HAMS significantly reduced diarrhea
duration and fecal weight when added to conventional iso-
osmolar glucose ORS [14].
We hypothesized that HAMS would reduce stool output and
diarrhea duration in cholera when substituted for glucose in a low
sodium hypo-osmolar ORS, thereby achieving what the hypo-
osmolar ORS per se does not achieve in cholera. This present study
in adults was designed to determine whether ORS efficacy could
be further increased by substituting HAMS for glucose in hypo-
osmolar ORS, an intervention that would have the consequences
of both further lowering osmolarity and providing carbohydrate
substrate to the colon for SCFA generation. A similar trial in
chidren under the age of five, with non-cholera diarrhea, was
registered along with this trial in adults but will be completed by a
different team and reported separately.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Consecutive patients presenting to the Emergency Services of the
Christian Medical College between May 2003 and June 2005, who
met the entry criteria and consented to participate, were referred to
the study medical officers. Patients were considered for eligibility if
they were males aged between 12–65 years with watery diarrhea of
less than 3 days duration, and moderate to severe dehydration [15]
at the time of presentation to the Emergency Services. Patients with
bloody diarrhea as well as those with co-existing medical illness,
including malignancy and clinical cardiopulmonary or liver disease,
were excluded. Women were excluded by convention because of
difficulty in separating diarrhea stool from urine. Patients were
resuscitated in the Emergency Services by intravenous infusion with
full strength Hartmann’s Ringer’s lactate solution, 100 ml/kg over
four hours. Doxycycline 300 mg in a single oral dose was given as
soon as the patient was capable of oral intake. Both these measures
represent the current standard of care for management of cholera at
this institution. The patient was admitted into the study ward after
obtaining consent.
Ethics
Individual participants gave written informed consent. The study
protocol and consent forms were approved by the Institutional
Review Board of the Christian Medical College, Vellore.
Interventions
After admission into the study, patients were randomly allocated
to receive one of two ORSs, either hypo-osmolar ORS (HO-ORS)
or HO-ORS in which glucose was completely replaced by 50 g/L
high amylose maize starch (National Starch, USA) (HAMS-ORS).
As can be seen from the composition of the two ORSs (Table 1),
there was no glucose in HAMS-ORS and the osmolarity of this
ORS was lower than of HO-ORS. Both ORSs were packaged in
sachets in quantities suitable for reconstitution to 200 ml with
water. Instructions regarding ORS reconstitution and intake, and
instructions regarding urine and stool collection were given to the
patient and his attendant. ORS was administered in a dose of
200 ml per hour and 200 ml after each loose stool. Intake of water
and other fluids was allowed and a standard Indian diet was
immediately allowed. Each stool was separately collected in a
bucket lined with a plastic bag, and the time and date noted on the
bag and weighed. Consistency and weight of each stool were
assessed and recorded by a paramedical worker who was unaware
of either the intervention received by the patient or the intent of
the study. This was done as the intervention could not be blinded
to the patient or the nursing team because of the distinctive
appearance of the two solutions. Assessment of stool consistency
was based on the Bristol stool form scale restricted to types V, VI
and VII, i.e formed, mushy and liquid stool [16]. Urine output was
recorded and monitored. Patients were evaluated at the end of
four hours by the study doctor and subsequently every four hours
if diarrhea continued or if urine output was not satisfactorily
established. Intravenous fluids (Ringer’s lactate) were administered
by the study doctor if systolic blood pressure lower than 110 mm Hg
was recorded following commencement of oral hydration or if the
patient had not passed urine within 8 hours after commencement of
oral hydration and had a persistently dry tongue. The study nurses
and doctors encouraged patients to take ORS according to the
schedule prescribed. Serum creatinine and electrolytes were
measured at presentation and repeated after 24 hours if normal.
In all others, repeat assessment was performed after 4 hours and
again at24 hours. Patientsremained inhospital for 48 hours or until
the stool consistency was reported as ‘formed’.
Objectives
The hypothesis was that substitution of amylase-resistant starch
for glucose in hypo-osmolar ORS would significantly reduce fecal
weight (volume) and diarrhea duration in adults with cholera or
cholera-like illness, with at least therapeutic equivalence in
hydration. The specific objectives were to conduct a randomized
controlled clinical trial in adults with cholera or cholera-like illness
using either hypo-osmolar glucose ORS or hypo-osmolar HAMS
Table 1. Composition of the two oral rehydration solutions
used.
Constituent HAMS-ORS HO-ORS
Glucose mM/L 0 75
Na mE/L 75 75
K mE/L 20 20
Cl mE/L 65 65
Citrate mE/L 30 30
HAMS 50 g/L 0
Osmolarity mOsm/kg 170* 245
HO-ORS refers to the currently WHO-recommended hypo-osmolar oral
rehydration solution, while HAMS-ORS refers to the same ORS wherein glucose
is replaced by amylase-resistant high amylose maize starch (HAMS).
*Excluding products of HAMS fermentation.
doi:10.1371/journal.pone.0001587.t001
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determine the effect on fecal weight, diarrhea duration, unscheduled
intravenous fluid administration, and total ORS intake.
Outcomes
Primary outcomes were: (1) Duration of diarrhea defined as
time from commencing ORS to first formed stool and (2) Total
diarrheal fecal weight. Secondary outcome measures included: (1)
Fecal weight in the time periods 0–12 hours, 13–24 hours, and
25–48 hours after commencing ORS; (2) Total ORS intake; (3)
Need for unscheduled intravenous fluids; and (4) Serum sodium of
134 mE/L or less. The occurrence of elevated serum creatinine
(.1.5 mg/dL) at 48 hours and of hypokalemia (serum K
,3.5 mmol/L) was also recorded.
Sample size
The study was designed as a randomized controlled clinical
trial. Sample size was calculated using PS Calc [17] based on data
in the control group from a previous study in patients with cholera
[14]. The aim was to ensure that addition of amylase-resistant
starch would reduce duration and weight of diarrhea to an extent
that would be considered as clinically significant by the user. Using
mean duration of diarrhea of 91 hours (SD 29 hours), and
adjusting for multiplicity of analyses, and allowing for 10%
dropout, enrolment of 25 patients per study arm would provide
80% power to detect reduction in duration of diarrhea by
28 hours (30% reduction) at the two sided 0.025 significance level.
Using the 0–48 hour fecal weight of 12040 g (SD 2751 g),
enrolling 25 patients per study arm would provide 90% power
to detect reduction in fecal weight by 3010 g (25% reduction) at
the two sided 0.025 significance level. Thus, we decided to enroll
50 patients for the study.
Randomization—Sequence generation
A table of random numbers was computer-generated by
randomization such that there was equal distribution among the
two groups in fifty participants. Sachets of the appropriate ORS
were packaged, as per the random table, in sealed opaque covers
bearing serial study numbers.
Randomization—Allocation concealment
When a participant entered the study, the next available serial
number was allocated and the cover bearing this serial number,
containing the packaged ORS, was handed by the study physician
to the nursing team. The sequence was concealed until the
interventions were assigned.
Randomization—Implementation
The allocation sequence was generated by SV prior to the start
of the study. Participants were enrolled by the study medical
officers (including VM and BKS) who assigned participants to
their groups by handing over the sealed cover bearing the next
serial study number (containing the appropriate packaged ORS) to
the study nurses.
Blinding
The participants could not be blinded to the intervention.
Those assessing the outcomes were blinded to group assignment.
The physicians assessing hydration of the patient were unaware of
the intervention received by the patient. The fecal weight was
assessed by a para-medical worker who was unaware of the exact
nature of the study and did not come into contact with the
participants.
Statistical methods
Survival curves were estimated by the Kaplan-Meier method and
compared using the log-rank test. Categorical variables were
reported as numbers and the Fisher exact test was used to assess
significanceof differences between groups.Continuousvariablesthat
were not distributed normally were reported as median with
interquartile range (IQR) and significance of differences between
groups tested using the Mann-Whitney U test. Continuous variables
that were normally distributed were reported as mean with standard
deviation (SD) and significance of differences between groups was
tested using the two-tailed unpaired Student t-test. A Bonferroni
correction was used to adjust for the multiple end points as well as
multipletime pointsforfecal weight(i.e.,0–12,13–24,25–48 hours).
Both unadjusted and adjusted P (Padj) values are presented. Two
tailed P values less than 0.05 were considered statistically significant.
Statistical analysis was performed using InStat for Windows version
3.06andPrism4forWindowsversion4.03(GraphPadSoftware,San
Diego California USA).
Results
Participant flow
50 adult males with acute watery diarrhea and moderate to severe
dehydration were included in this study. Figure 1 presents the flow
chart for participants enrolled in the study. Patients who were
excluded from the study included those with diarrhea duration
longer than three days at presentation, and one patient with
persistent vomiting and abdominal distension who could not receive
oral fluids. Those with pre-existing medical conditions including
hypertension and/or diabetes mellitus, renal failure, heart disease,
gastrointestinal and liver disease, and internal malignancy, were
mostlypatientswho werevisiting this tertiaryreferral carehospital in
south India for medical attention and had developed a diarrheal
illness during travel or during their stay in this town.
Recruitment
Participants were recruited from among consenting patients
seen in the Emergency Services between May 2003 and June
2005. During the same period, a total of 913 patients with acute
diarrhea were admitted to the hospital.
Baseline data
The baseline demographic and clinical characteristics of the
participants in each group are shown in Table 2. None of the
patients included in this study required dialysis for renal failure.
There was no mortality in this study.
Numbers analyzed
All 50 participants completed the study and their data was
analyzed.
Outcomes and estimation
The time (median, IQR) to first formed stool (duration of
diarrhea) was significantly reduced in patients receiving HAMS-
ORS (19.0 hours, IQR 10-28) compared to those receiving HO-
ORS (42.0 hours, 24–50) (P,0.001, Padj,0.001). One patient in
the HO-ORS group had prolonged diarrhea lasting longer than
four days. The difference between the two groups remained highly
significant even when this outlier value was excluded.
Survival analysis showed significantly more rapid recovery from
diarrhea in the HAMS-ORS group compared to the HO-ORS
group (P,0.0001, log rank test) (Figure 2).
Total fecal weight (in grams, median, IQR) from entry into the
study until the first formed stool was substantially less but not
HAMS for Dehydrating Diarrhea
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1160–5635 g) compared to the HO-ORS group (5210, 2095–
12190 g) (P=0.04, Padj=0.08) (Figure 3). When analyzed
according to the time period when the reduction in stool weight
occurred, fecal weight during the first 12 hours of the study was
found to be similar in the HAMS-ORS group (1970, 1005–
4565 g) compared to the HO-ORS group (2160, 1285–4870 g)
(P=0.51) (Figure 3), whereas in the second 12 hours after
commencing ORS fecal weight was significantly lower in the
HAMS-ORS group (280, 0–965 g) compared to the HO-ORS
group (1360, 405–2985 g) (P=0.008, Padj=0.048). Fecal weight in
the 24–48 hour study period was also significantly lower in the
HAMS-ORS group (0, 0–360 g) compared to that of the HO-
ORS group (1080, 55–3485 g) (P=0.002, Padj=0.01).
ORS intake (median, IQR) in the first and second 12 hours after
admission was similar in the HAMS-ORS group (4400, 3200–
5600 ml and 2200, 1450–2800 ml) and the group receiving HO-
ORS (4400, 3000–6100 ml and 2200, 1700–3700 ml) (P=0.79 and
0.46 respectively). However, in the second 24 hour period after
entry, ORS intake was significantly lower in the HAMS-ORS group
(0, 0–1450 ml) compared to the HO-ORS group (2200, 1500–
4300 ml)(Padj,0.001)(Figure4).Fortheentire48 hourperiodthere
was no statistically significant difference of ORS intake in the group
receiving HAMS-ORS (7200, 5700–10050 ml) compared to HO-
ORS (10000, 6200–13100 ml) (Padj=0.12).
Administration of intravenous fluids after commencement of
ORS was considered necessary in 9 patients randomized to
HAMS-ORS compared to 12 patients randomized to HO-ORS
(P=0.56) (Table 3). All these patients required IV fluids within the
first 24 hours of admission. There was no significant difference in
the amount of fluid required (Table 3).
Ancillary analyses
Subgroup analysis was performed to compare stool weight and
diarrhea duration in patients with positive stool culture for Vibrio
Figure 1. CONSORT flow diagram
doi:10.1371/journal.pone.0001587.g001
Table 2. Demographic characteristics of patients enrolled in
the study.
HAMS-ORS
(n=25)
HO-ORS
(n=25)
Age (in years) Mean6SD 42.6612.0 37.8613.7
Range 24–65 18–63
Diarrhea duration prior to admission (hours)
Mean6SD 24.4612.6 27.5617.7
Range 9–48 2–72
Weight (kG) 62.264.7 63.165.0
Systolic blood pressure at admission (mm Hg) 75639.7 70644.3
Diastolic blood pressure at admission (mm Hg) 37638.3 39636.0
Serum creatinine at admission (mg/dL) 1.861.1 2.060.90
Serum Na at admission (mEq/L) 138.766.1 139.264.8
Serum K at admission (mEq/L) 4.260.53 4.460.99
Pathogens isolated
V. cholerae O1 8 11
V. cholerae non-O1, non-O139 2 1
Values shown are mean6SD except for pathogens isolated which are actual
numbers of patients from whom they were isolated.
doi:10.1371/journal.pone.0001587.t002
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was no difference in recovery from diarrhea between Vibrio positive
and Vibrio negative patients. Treatment with ORS type, not the
presence of cultivable Vibrio, was the determinant of recovery time
(Figure 5). In the Vibrio positive subgroup, both diarrhea duration
and total stool weight were significantly lower in the HAMS-ORS
group compared to HO-ORS group (Padj=0.008 and Padj=0.025
respectively).
Adverse events
Hyponatremia (serum sodium less than 134 mEq/L) was noted
in 4 patients in the HAMS-ORS group and 3 patients in the HO-
ORS group prior to ORS treatment, and in 3 and 2 patients in the
respective groups 24 hours after commencement of ORS. None of
these patients had any clinical deficit. Four of the 5 patients who
had serum sodium of 134 mE/L or less at 24 hours were the same
as the ones who had low levels at entry. One patient who received
HO-ORS had serum sodium of 136 mE/L at entry and sodium of
128 mE/L at 24 h. There was no significant difference in serum
potassium or serum creatinine between the two groups.
Discussion
The present study demonstrates that diarrhea duration and
fecal weights 13–48 hours after start of oral therapy were reduced
in cholera and cholera-like diarrhea by treatment with a hypo-
osmolar HAMS-containing ORS compared to hypo-osmolar
glucose ORS. The findings are particularly important because
reduction in diarrhea of the magnitude noted in these studies has
not been achieved by hypo-osmolar glucose ORS which at best
Figure 2. Recovery from diarrhea shown as residual proportion
of patients with diarrhea at each time point after commence-
ment of ORS. The difference between high amylose maize-ORS
(HAMS) and hypo-osmolar-ORS (HO) was statistically highly significant
(P,0.0001, log-rank test).
doi:10.1371/journal.pone.0001587.g002
Figure 3. Fecal weight during the time periods 0–12 hours, 13–
24 hours, and 25–48 hours after commencement of ORS and
total diarrheal fecal weight. The box and whiskers plots show
median and IQR (box) and lowest and highest value (whiskers). Two-
tailed adjusted P values (Mann-Whitney) show the significance of
differences between HAMS and HO ORS for that particular time period.
doi:10.1371/journal.pone.0001587.g003
Figure 4. ORS intake in mL during the time periods 0–12, 13–
24, and 25–48 hours and total ORS intake (last two box plots).
The box and whiskers plots show median and IQR (box) and lowest and
highest value (whiskers). Two-tailed adjusted P values (Mann-Whitney)
show the significance of differences between HAMS and HO ORS for
that particular time period.
doi:10.1371/journal.pone.0001587.g004
Table 3. Biochemical parameters after therapy and other
measures in the two study arms.
HAMS-ORS HO-ORS P
Serum [Na] mEq/L 138.364.5 138.564.3 0.75
Serum [K] (mEq/L) 4.2560.58 4.4260.49 0.30
Serum creatinine (mmol/L) 1.3360.63 1.3160.52 0.69
Serum sodium #134 mEq/L on admission 4 3 1.00
Serum sodium #134 mEq/L at 24 hours 3 2 1.00
Unscheduled IV before 24 h 9 patients 12 patients 0.56
Amount of unscheduled IV fluid given (mL) 14406490 12106420 0.47
Amount of water ingested (mL)
0–12 h 1946382 1856357 0.93
13–24 h 3126437 2626388 0.67
25–48 h 6406795 5626623 0.70
Urine output (mL)
0–12 h 14776900 186361643 0.31
13–24 h 172961156 12856807 0.13
25–48 h 179861469 194061149 0.76
Values shown are absolute numbers of patients or mean6SD.
doi:10.1371/journal.pone.0001587.t003
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all in adults with cholera [18].
Previous studies suggest that when diarrhea duration is reduced
by an intervention, total fecal weight is also reduced. In this study,
although there was a substantial decrease in stool output for the
entire 48 hours (5210 vs 2190 g), the difference between the two
groups did not reach statistical significance primarily because the
initial 0–12 hour stool collection did not reveal any decrease (1970
vs 2160 g). Significant differences in fecal weight (which can be
perceived as severity of diarrhea) became apparent only after the
first 12 hours suggesting that there was a latent period before the
action of HAMS-ORS. This supports the hypothesis that the effect
of HAMS is secondary to metabolism and absorption in the colon.
Two major end points were studied, i.e. diarrheal stool loss and
duration of diarrhea. Since there were multiple analyses, a
Bonferroni correction was applied, and significant differences were
noted between the two groups in diarrhea duration as well as in fecal
weight after the first 12 hours. In the prior study of HAMS-ORS
using an iso-osmolar ORS solution in patients with cholera [14], a
reduction in stool output in the HAMS group was also not observed
in the initial 12 hour period consistent with the hypothesis that
HAMS is enhancing colonic fluid absorption that will be evident
only in later time periods. Attenuation of the mucosal cyclic AMP
response by butyrate produced from amylase resistant starch is
another possible explanation for the beneficial effect of HAMS and
mayaccountforthetimelagbetweenHAMSadministrationandthe
reduction in diarrhea. The contribution of these and other
mechanisms to the HAMS effect remains to be elucidated.
ORS use is based on the concept that absorptive and secretory
processes in the intestine and colon are separate and distinct; that
stimulation of secretion does not affect absorption; and that
enhancement of absorption does not alter secretion. Cyclic AMP
induces fluid and electrolyte secretion, but enhances glucose-
stimulated sodium absorption [19], and thus glucose ORS
enhances sodium and water absorption despite persistence of fluid
secretion. In acute diarrhea, the colonic capacity for absorption of
water of approximately 5 liters per day [20] is not utilized because
of a depletion of luminal short chain fatty acids (SCFA) [21]. High
amylose maize starch (HAMS) contains a mixture of digestible and
amylase-resistant starches. The digestible component provides
glucose in the small intestine for facilitating sodium absorption.
The amylase-resistant component results in an increase of colonic
luminal concentrations of SCFA [22]. SCFA production in the
colon is difficult to measure because of the extremely rapid
absorption and metabolism leading to their disappearance from
colonic lumen and feces, and is usually inferred indirectly from the
amount of substrate administered and the amount recovered from
feces. We have previously demonstrated that fecal recovery of
HAMS administered into the stomach of patients with cholera was
only 16% [14], indicating that over 80% of the administered
amylase resistant starch had been utilized, presumably by
fermentation to SCFA in the colon. It must be noted that
standard therapy for cholera also included the early introduction
of normal food which included rice and other cereals which can
also provide substrate for colonic fermentation to short chain fatty
acids. This intervention probably contributed to the beneficial
effect in the HAMS group by leading to an increased colonic
carbohydrate load in the latter patients. In the present study a
single oral dose of doxycycline was administered as part of
standard clinical practice for the treatment of cholera. Adminis-
tration of an antibiotic, to which the cholera Vibrio is sensitive, has
been shown to significantly shorten diarrhea [23]. Vibrio cholerae
isolates from southern India are presently sensitive to tetracycline
although isolates from several parts of the world exhibit
tetracycline-resistance. It has been shown that the anaerobic
bacterial flora of the colon, which is responsible for starch
fermentation to SCFA, is not affected by oral doxycycline [24].
Participants in this study had severe acute watery diarrhea with
significant dehydration at presentation, necessitating initial
intravenous rehydration. Although fecal culture was positive for
Vibrio cholerae only in 22 of these 50 patients, in southern India,
severely dehydrating acute infective diarrhea in adults is almost
always due to cholera. Such diarrhea may also be caused by
enterotoxigenic E. coli that elaborate heat labile enterotoxin and
produce a syndrome similar to cholera [25]. Standard bacterial
cultures did not reveal the presence of any other bacterial
enteropathogens in these patients, nor were parasites noted in any
of the patients; however we did not test for enterotoxigenic E. coli.
When sub-group analysis was done on those patients with positive
stool cultures for Vibrio cholerae, the difference between the two
treatment groups remained statistically highly significant. In an
earlier study, our group demonstrated that addition of HAMS to
conventional (iso-osmolar) glucose ORS reduced diarrhea dura-
tion and fecal weight in patients with cholera [14]. Children with
non-cholera diarrhea possibly represent a different group by virtue
of the different spectrum of pathogens that cause diarrhea. The
ability of colonically-absorbed carbohydrate to shorten diarrhea in
children has been examined with variable results. HAMS and
partially hydrolysed guar gum both shortened diarrhea compared
to conventional iso-osmolar glucose ORS [26,27]. However, a
mixture of colonically-absorbed carbohydrates did not shorten
diarrhea when compared to reduced osmolarity glucose ORS
[28]. The latter finding can be ascribed either to the small amount
of colonically-absorbed carbohydrate that was added or to the
comparison with a reduced osmolarity ORS which may already
have maximally increased absorption. The present study is
different in that it examined the possibility that HAMS could
reduce diarrhea in adult patients with cholera treated with a low
sodium hypo-osmolar ORS.
The large volume of ORS given in both trial arms resulted from
following the recommendation to administer 200 ml of ORS every
Figure 5. Recovery from diarrhea in patients with positive
cultures for Vibrio cholerae compared with those with negative
cultures. Significant differences were noted between HAMS and HO
ORS-treated patients in patients whose stool culture revealed Vibrio
cholerae (log rank test, P,0.001). Significant differences were noted
between HAMS and HO ORS-treated patients also in the group of
patients whose stool culture did not grow Vibrio cholerae (log rank test,
P=0.006). The Vibrio-positive subgroup was not statistically significantly
different from the group that was negative by culture, whether it was
HAMS or HO-ORS, and the Vibrio-positive subgroup showed signifi-
cantly quicker recovery when treated with HAMS.
doi:10.1371/journal.pone.0001587.g005
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the stool became formed. This large volume of ORS led to
increased urine volume in both groups. Although not to be
recommended as physiological, the apparently excessive ORS
administration and urine volume served to protect against acute
renal failure which remains a significant complication in patients
with acute severely dehydrating watery diarrhea. Despite the
excessive ORS administration, ORS intake in the period 25–
48 hours after commencement of treatment was significantly less
in the HAMS-ORS group (median 0 ml) compared to the HO-
ORS group (median 2200 ml). It is possible that total ORS intake
would have been much less in both groups had intake been exactly
matched to stool output. Thus, as earlier mentioned in connection
with fecal volumes, the methodology used could possibly have
confounded the outcomes by affecting the parameters measured.
Concerns have been raised about the possibility of symptomatic
hyponatremia in patients with cholera treated with HO-ORS [29].
In the present study, we did not observe symptomatic hyponatre-
mia in any of the patients. However, the numbers of patients
included in this study were small. In order to be powered to detect
significant hyponatremia in any treatment arm, the study would
have had to include a much larger number of participants, but this
was not the primary study aim. The rates of unscheduled
intravenous infusion in this study were higher than in other
studies of oral rehydration. The overall failure rate of oral
rehydration in community practice is considered to be in the range
of 1%. However, this hospital-based study recruited patients with
severe diarrhea, and supplemental intravenous fluids were given in
patients who failed to pass urine within the first eight hours after
completion of IV hydration in order to ensure that they would not
develop renal failure. The need for such IV fluid administration
was equal in the two study arms. The administration of fixed
quantities of oral rehydration solution in this study, instead of
replacing stool volume with equivalent amounts of ORS, may also
have led to a higher incidence of unscheduled intravenous fluid
administration.
In designing a new ORS that would reduce stool weight and
diarrhea duration, we felt that it would be important for the
difference to be not only statistically significant but also both
quantitatively appreciable and clinically substantial. In the present
study, substitution of glucose in hypo-osmolar ORS by high
amylose maize starch reduced the duration of diarrhea by 55%
and very significantly reduced fecal weight after the first 12 hours
of illness. Hypo-osmolar ORS has become the recommended
standard of therapy for the oral therapy of cholera. However in
patients with cholera, hypo-osmolar ORS does not reduce fecal
weight or shorten diarrhea [6]. Cholera and similar severe watery
diarrhea often occurs in resource-poor countries or in refugee
camps. In such situations, especially when it occurs in epidemics,
the use of ORS containing HAMS may be of particular benefit in
shortening diarrhea, hospitalization, and reducing costs.
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